Abstract: A dental fluoride foam composition comprising an aqueous solution of a water soluble fluoride ion releasable salt, a surfactant selected from the group consisting of nonionic surfactants, zwitterionic surfactants, betaine surfactants and mixtures thereof; and an orally compatible acidifying agent in an amount sufficient to adjust the pH of the composition to about 3 to about 5. The composition is stable at low temperatures and is a clear solution substantially free of precipitates when held at 4.4° C. for 12 hours. When dispensed from a container into the trough of a dental tray, the composition forms a low density, rapidly collapsible foam which substantially liquefies in about 1 minute after being dispensed from the foam generating container and placed in contact with a patient's teeth.

Abstract: Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: A method of treating a disease or condition for which a JAK inhibitor is indicated in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, and particularly, a method for the treatment of various inflammatory diseases, particularly psoriasis, asthma and COPD.

Abstract: Flavour components for use in oral care compositions containing a metal salt, compositions comprising the flavour components, and methods of making and using the same. The flavour components comprise a taste -masking agent comprising cinnamic aldehyde, eugenol and eucalyptol and one or more flavouring agents selected from L-menthol, N-ethyl-p-menthane-3-carboxamide, anethole, peppermint oil, spearmint oil and corn mint oil. In particular the metal salt is zinc citrate.

Abstract: The present invention relates to compounds of formula (I): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD.

Abstract: Described herein are compositions comprising combinations of metal salts, and methods of preparing and using the same.

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: The present invention relates to compounds of formula (I): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD.

Abstract: A dentifrice composition having a low water phase comprising effective amounts of polyphosphate and ionic active ingredients.

Abstract: A cooling system for use in cooling an electrical component of a wind turbine is described herein. The cooling system includes a first heat exchange assembly that is coupled to the electrical component. The first heat exchange assembly is configured to transfer heat from the electrical component to a cooling fluid. A fluid distribution assembly is coupled to the first heat exchange assembly for selectively channeling the cooling fluid to the first heat exchange assembly. The fluid distribution assembly is configured to adjust a flowrate of the cooling fluid being channeled to the first heat exchange assembly to adjust a temperature of the component.

Abstract: Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: This invention relates to compounds, pharmaceutical compositions and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) wherein R1, R2 and R3 are as defined in this specification.

Abstract: A system and method manages Quality-of-Service (QoS) in a network by allocating resources, such as available network bandwidth. The network devices transmit and receive data traffic streams, each of which includes QoS parameters, including a priority level and bandwidth allocation. The method includes choosing which existing QoS allocations are pre-empted, notifying original requesters of pre-empted allocations, and re-establishing pre-empted allocations with appropriate modifications. If a new QoS request cannot be accommodated due to the previous allocations to lower-priority requesters, the existing lower-priority allocations are released until enough allocations are released to accommodate the new request. Once the new request is allocated, the pre-empted configurations may be reallocated.

Abstract: A method and system for automatically controlling home appliances based on an estimated time of arrival (ETA) of a resident at his or her home. In one aspect of the invention, a system for controlling a home appliance comprises a mobile electronic device (MED) and a home automation system (HAS), wherein the MED determines that a homeward bound condition is met and in response to determining that the homeward bound condition is met commences reporting whereby the HAS acquires ETA information for a resident based in part on device location information acquired by the MED, and wherein the HAS determines based in part on the ETA information that an ETA condition is met and in response to determining that the ETA condition is met executes a control action that controls the home appliance.

Abstract: A dental fluoride foam composition comprising an aqueous solution of a water soluble fluoride ion releasable salt, a surfactant selected from the group consisting of nonionic surfactants, zwitterionic surfactants, betaine surfactants and mixtures thereof; and an orally compatible acidifying agent in an amount sufficient to adjust the pH of the composition to about 3 to about 5. The composition is stable at low temperatures and is a clear solution substantially free of precipitates when held at 4.4° C. for 12 hours. When dispensed from a container into the trough of a dental tray, the composition forms a low density, rapidly collapsible foam which substantially liquefies in about 1 minute after being dispensed from the foam generating container and placed in contact with a patient's teeth.

Abstract: A system and method manages Quality-of-Service (QoS) in a network by allocating resources, such as available network bandwidth. The network devices transmit and receive data traffic streams, each of which includes QoS parameters, including a priority level and bandwidth allocation. The method includes choosing which existing QoS allocations are pre-empted, notifying original requesters of pre-empted allocations, and re-establishing pre-empted allocations with appropriate modifications. If a new QoS request cannot be accommodated due to the previous allocations to lower-priority requesters, the existing lower-priority allocations are released until enough allocations are released to accommodate the new request. Once the new request is allocated, the pre-empted configurations may be reallocated.

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: (I) wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2a, Rx, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, X2k, R2l, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: A system and method in a local area network based on the Universal-Plug-and-Play (UPnP™) technology represents an infrared (IR) remote control (RC) pass-through protocol in the Content Directory Service (CDS) of a media server that transmits an audio-video (AV) media stream over the network to a media renderer. The CDS includes a listing of media content items that represent media source devices that provide media content to the media server, and a listing of associated IR pass-through protocol identifiers (IRPT-IDs) for each media content item. Each IRPT-ID identifies an IR pass-through encoding/decoding protocol usable by the IR decoder in the media server and each IRPT-ID has an associated internet protocol (IP) connection point (IRPT-CP). The media renderer browses the CDS to identify the media content item and its associated IRPT-ID/IRPT-CP pair. The IR RC at the media renderer sends RC commands to the media renderer that are encoded using the IR pass-through protocol represented by the IRPT-ID.